Financial Performance - The company's revenue for Q3 2022 reached ¥1,658,020,093.78, representing a 28.45% increase year-over-year[3] - Net profit attributable to shareholders was ¥542,739,578.90, an increase of 11.73% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses was ¥542,048,671.13, up by 9.92% year-over-year[3] - The company's operating income for the year-to-date reached ¥4,951,543,979.15, a significant increase of 62.53% year-over-year, driven by growth in imported albumin sales[6] - Total revenue for the current period reached ¥4,951,543,979.15, a significant increase from ¥3,046,522,817.78 in the previous period, representing a growth of approximately 62.5%[15] - Operating profit for the current period was ¥1,900,857,794.52, compared to ¥1,588,850,419.93 in the previous period, indicating an increase of about 19.6%[16] - Net profit attributable to shareholders of the parent company was ¥1,603,811,643.64, up from ¥1,396,174,488.18, reflecting a growth of approximately 14.9%[16] - The comprehensive income attributable to the parent company for the current period was ¥3,072,458,542.24, compared to ¥1,305,441,786.15 in the same period last year[17] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥30,228,237,255.47, reflecting a 10.98% increase from the end of the previous year[3] - Total assets increased to ¥30,228,237,255.47 from ¥27,236,582,048.82, marking a rise of about 11.6%[15] - Non-current assets totaled ¥22,287,466,066.89, up from ¥20,364,331,133.06, which is an increase of approximately 9.4%[15] - Current liabilities rose to ¥1,422,394,257.08 from ¥1,306,625,745.51, representing an increase of about 8.9%[15] - Total liabilities increased to ¥1,422,394,257.08 from ¥1,306,625,745.51, indicating a rise of about 8.9%[34] - The total equity attributable to shareholders of the parent company rose to ¥28,786,765,664.31 from ¥25,902,445,517.58, indicating an increase of approximately 11.1%[15] Cash Flow - Cash flow from operating activities for the year-to-date was ¥1,203,356,366.64, showing a slight increase of 1.96% compared to the previous year[3] - The company's cash and cash equivalents as of September 30, 2022, amounted to approximately ¥3.17 billion, an increase from ¥2.75 billion at the beginning of the year[13] - The company reported a net cash increase of ¥-68,862,752.42 in cash and cash equivalents for the current period[19] - The net increase in cash and cash equivalents was CNY -68,862,752.42, compared to a positive increase of CNY 159,074,397.72 in the prior year, indicating liquidity challenges[39] Shareholder Information - The total number of common shareholders at the end of the reporting period was 121,818[7] - GRIFOLS, S.A. is the largest shareholder, holding 26.20% of shares, equivalent to 1,766,165,808 shares[7] - The second largest shareholder, RAAS CHINA LIMITED, holds 5.83% of shares, totaling 392,878,676 shares[7] Research and Development - Research and development expenses increased by 31.32% to ¥102,089,434.95, indicating a focus on enhancing project development[6] - Research and development expenses for the current period were ¥102,089,434.95, compared to ¥77,743,274.40 in the previous period, showing an increase of approximately 31.3%[16] Operating Costs - The company experienced a 93.00% increase in operating costs, amounting to ¥2,716,933,294.97, largely due to the higher proportion of imported albumin sales[6] - The total operating costs for the current period were ¥3,352,262,703.29, up from ¥1,899,585,559.02, indicating an increase of about 76.7%[36] Other Financial Metrics - The company's basic earnings per share for the period was ¥0.081, a 12.50% increase compared to the same period last year[3] - The company's weighted average return on net assets was 5.86%, an increase of 0.43 percentage points year-on-year[23] - Other comprehensive income after tax for the current period was ¥1,468,646,898.60, a significant improvement from -¥90,732,702.03 in the previous period[16]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 3,293,523,885.37, representing an increase of 87.59% compared to CNY 1,755,724,588.09 in the same period last year[13]. - The net profit attributable to shareholders of the listed company was CNY 1,061,072,064.74, up 16.55% from CNY 910,429,461.76 year-on-year[13]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 1,058,972,524.69, reflecting a 14.60% increase from CNY 924,079,257.01 in the previous year[13]. - The net cash flow from operating activities was CNY 764,952,685.41, which is a 33.88% increase compared to CNY 571,392,608.76 in the same period last year[13]. - Basic earnings per share were CNY 0.157, an increase of 16.30% from CNY 0.135 in the previous year[13]. - The total assets at the end of the reporting period were CNY 28,998,624,640.89, a 6.47% increase from CNY 27,236,582,048.82 at the end of the previous year[13]. - The net assets attributable to shareholders of the listed company were CNY 27,460,676,505.19, up 6.02% from CNY 25,902,445,517.58 at the end of the previous year[13]. - The weighted average return on net assets was 3.96%, an increase of 0.39 percentage points from 3.57% in the previous year[13]. - The company reported a comprehensive income of CNY -555,535,423.29 for the first half of 2022, an improvement from CNY -1,240,845,030.34 in the same period of 2021[131]. - The total profit for the first half of 2022 was CNY 1,263,803,505.79, up 23.4% from CNY 1,024,465,706.37 in the same period of 2021[134]. Revenue Sources - Revenue from blood products production and sales was ¥3,292,768,512.38, accounting for 99.97% of total revenue, with a year-on-year increase of 87.60%[31]. - Albumin sales surged to ¥2,144,745,502.59, representing a 207.26% increase year-on-year[31]. - Import of albumin saw a dramatic rise to ¥1,409,961,396.69, marking an increase of 1,748.42% compared to the previous year[32]. - The East China region generated ¥1,172,307,264.26 in revenue, reflecting an 87.90% increase year-on-year[32]. Investment and Acquisitions - The company has successfully integrated acquisitions, enhancing its core competitiveness and significantly increasing raw plasma collection volume[27]. - The company has completed the acquisition of Zhejiang Haikang's equity using RMB 24,522.05 million from the remaining fundraising[46]. - The acquisition of Zhejiang Haikang equity was completed on December 26, 2016, with a total transaction price of CNY 369 million for 90% of the equity[56]. - The company has a 45% stake in GDS, with an asset scale of 13.905 billion RMB, located in Europe and the United States, focusing on procurement, manufacturing, and sales of medical and blood testing products[36]. Research and Development - Research and development investment increased by 46.03% to CNY 64.23 million, reflecting the company's commitment to project development[30]. - Research and development expenses increased to CNY 64,231,731.95, up 46.0% from CNY 43,985,695.12 in the prior period[134]. Risk Management - The management has highlighted potential risks and corresponding measures in the report, which investors are advised to review[2]. - The company faces risks related to the supply of raw materials, with a focus on enhancing management of plasma collection stations to increase supply capacity[61]. - The company has a risk of goodwill impairment due to the consolidation of subsidiaries, which requires annual impairment testing[63]. Environmental Compliance - The company’s wastewater treatment process includes regulation, acid hydrolysis, aerobic treatment, contact oxidation, and disinfection[70]. - The company has implemented noise reduction measures in its facilities to ensure compliance with noise standards[74]. - All companies reported no administrative penalties due to environmental issues during the reporting period, reflecting strong compliance[87]. - Shanghai Laishi obtained the "2019 Annual Environmental Protection Advanced Collective" award in April 2020[91]. Shareholder Information - Grifols, S.A. holds 1,766,165,808 shares, representing 26.20% of the total shares, and is the largest shareholder[115]. - The second-largest shareholder, RAAS China Limited, holds 495,769,852 shares, accounting for 7.35% of the total[115]. - The company has a total of 126,480 common shareholders at the end of the reporting period[115]. - The report indicates that 484,528,274 shares held by Grifols, S.A. are pledged[115]. Financial Management - The company has established a fundraising management system in compliance with relevant laws and regulations to ensure proper use and storage of funds[47]. - The total amount of raised funds is 638.7271 million RMB, with 170.10 thousand RMB used in the current period and a cumulative usage of 578.7344 million RMB[43]. - The company has not changed the purpose of the raised funds during the reporting period, with 7.71387 million RMB remaining unused[43]. Operational Efficiency - The company aims to enhance its quality assurance system to address potential safety risks associated with blood products[60]. - The company plans to continue expanding its market presence and invest in new product development[149]. - The company aims to enhance its operational efficiency and explore potential mergers and acquisitions to drive growth[149]. Accounting Policies - The financial statements comply with the accounting standards set by the Ministry of Finance, accurately reflecting the company's consolidated financial position as of June 30, 2022[163]. - The company has implemented new financial instrument standards and revenue recognition standards since 2019, ensuring compliance with the Ministry of Finance's regulations[161]. - The company categorizes receivables into groups based on historical experience and aging to estimate expected credit losses[185].

Financial Performance - The company's operating revenue for Q1 2022 was RMB 1,685,498,423.72, representing a 97.32% increase compared to RMB 854,205,643.53 in the same period last year[4]. - Net profit attributable to shareholders was RMB 548,033,363.89, up 28.63% from RMB 426,048,265.01 year-on-year[4]. - The net cash flow from operating activities increased by 44.25% to RMB 415,302,906.87, compared to RMB 287,898,726.08 in the previous year[4]. - The basic and diluted earnings per share were both RMB 0.081, reflecting a 28.57% increase from RMB 0.063 in the same period last year[4]. - The net profit margin improved to approximately 32.4% in Q1 2022, compared to 49.7% in the same period last year, indicating a shift in profitability dynamics[17]. - The total profit for Q1 2022 was CNY 645,212,896.49, an increase of 35.6% from CNY 475,740,853.68 in Q1 2021[39]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 27,698,268,156.38, a 1.70% increase from RMB 27,236,582,048.82 at the end of the previous year[4]. - The total assets of Shanghai RAAS Blood Products Co., Ltd. reached approximately CNY 27.70 billion as of March 31, 2022, an increase from CNY 27.24 billion at the beginning of the year, reflecting a growth of about 1.68%[12][13]. - The company's total liabilities decreased slightly to ¥1,314,844,595.07 from ¥1,332,415,396.48, showing a reduction of approximately 1.3%[15]. - The company's accounts payable decreased to CNY 933.69 million from CNY 966.05 million, a reduction of approximately 3.35%[13]. Cash Flow - The company's cash and cash equivalents amounted to CNY 3.02 billion, up from CNY 2.75 billion at the beginning of the year, representing an increase of approximately 10.05%[12]. - The cash flow from operating activities netted CNY 415,302,906.87, compared to CNY 287,898,726.08 in the previous year, indicating a rise of 44.3%[42]. - The company reported a net cash outflow from investing activities of ¥66,788,256.17, an improvement from a net outflow of ¥85,298,102.62 in the same period last year[26]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 132,064, with the largest shareholder, GRIFOLS, S.A., holding 26.20% of the shares[10]. - The total equity attributable to shareholders increased to ¥26,383,748,240.39 from ¥25,902,445,517.58, reflecting a growth of about 1.8%[36]. Research and Development - Research and development expenses rose by 62.59% to RMB 34,400,140.41, driven by increased R&D activities[9]. - The company is actively engaged in research and development of new products and technologies to enhance its market position[11]. - The company reported R&D expenses of ¥34,400,140.41 for Q1 2022, an increase from ¥21,157,204.66 in the same period last year, representing a growth of approximately 62.3%[38]. Investment Income - The company reported a decrease in investment income by 30.15% to RMB 110,489,501.71, attributed to reduced investment income from associated companies[9]. - The company's investment income decreased by 30.15% to CNY 110,489,501.71, primarily due to reduced investment returns from associated companies[31]. Future Outlook - Future outlook includes plans for market expansion and potential mergers and acquisitions to drive growth[11].

Financial Performance - The company's operating revenue for 2021 was ¥4,287,726,749.67, representing a 55.26% increase compared to ¥2,761,682,036.39 in 2020[14]. - The net profit attributable to shareholders for 2021 was ¥1,294,510,050.46, a decrease of 2.21% from ¥1,323,711,055.48 in 2020[14]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥1,368,820,159.04, an increase of 3.96% from ¥1,316,680,599.25 in 2020[14]. - The net cash flow from operating activities for 2021 was ¥1,294,013,219.19, a 10.71% increase from ¥1,168,847,146.49 in 2020[14]. - The total assets at the end of 2021 were ¥27,236,582,048.82, a 6.84% increase from ¥25,493,798,616.93 at the end of 2020[14]. - The net assets attributable to shareholders at the end of 2021 were ¥25,902,445,517.58, a 3.10% increase from ¥25,122,780,033.73 at the end of 2020[14]. - The company reported a basic earnings per share of ¥0.19 for 2021, down 9.52% from ¥0.21 in 2020[14]. - In 2021, the company achieved operating revenue of 4.288 billion yuan, a 55.26% increase from 2.762 billion yuan in the previous year, and a net profit attributable to shareholders of 1.295 billion yuan, a decrease of 2.21% from 1.324 billion yuan[31]. - The revenue from blood products was ¥4,284,719,023.99, accounting for 99.93% of total revenue, with a year-on-year growth of 55.20%[40]. Dividend Distribution - The company plans to distribute a cash dividend of 0.28 RMB per 10 shares (including tax) to all shareholders, with no bonus shares issued[3]. - The cash dividend distribution represents 100% of the total profit distribution amount, adhering to the company's policy of a minimum of 80% cash dividend in mature stages[125]. - The total cash dividend paid in 2021 was RMB 168,519,697.68 (including tax) for the previous year's profit distribution[125]. - The company's net profit for the year 2021 was RMB 773,898,460.31, with a distributable profit of RMB 2,564,671,592.65 after accounting for a 10% legal reserve[125]. Market and Industry Trends - The blood products industry experienced continuous growth in raw plasma supply, maintaining a tight balance between supply and demand[20]. - The company anticipates that the market concentration in the blood products industry will increase as leading enterprises gain advantages due to differentiated technology and optimized product structures[20]. - The blood product industry in China is experiencing a high demand, with a significant gap between supply and demand expected to persist in the short term[22]. - The industry is characterized by high entry barriers and strict regulations, with only about 30 operational blood product companies in China[21]. - The company is benefiting from the ongoing consolidation in the blood product industry, which is expected to increase market concentration[23]. Product and Technology Development - The company is focused on expanding its market presence and developing new products and technologies[3]. - The company is actively restructuring its marketing system to enhance channel coverage and strengthen its market share in key academic regions[24]. - The company has established a long-term cooperative mechanism with key opinion leaders (KOLs) to boost its sales channels[24]. - The company is focusing on improving technology and increasing the comprehensive utilization rate of plasma to enhance its competitive advantage[22]. - The company is in the pre-clinical development stage for several new products, including subcutaneous human immunoglobulin and activated prothrombin complex, aimed at enhancing product variety and competitiveness[53]. - The company is preparing for the registration of several new products, including human hepatitis B immunoglobulin and rabies immunoglobulin, which are expected to enhance the product line[53]. Risks and Challenges - The company faces risks including raw material supply risks, rising plasma costs, potential product safety risks, and goodwill impairment risks[3]. - There is a risk of insufficient raw material supply for plasma, which directly impacts production scale; the company plans to enhance management of plasma collection stations and increase their capacity[86]. - Rising costs of plasma collection are a concern due to increased labor income and inflation; the company aims to optimize technology and improve donor retention rates[86]. - The company has recognized goodwill impairment risks following the acquisition of Zhengzhou Laisai, Tonglu Biology, and Zhejiang Haikang, which may affect financial performance if these subsidiaries face significant operational challenges[87]. Governance and Management - The company has a diverse board with members holding various significant positions in other organizations, enhancing its governance[98]. - The company’s governance structure includes a remuneration and assessment committee responsible for evaluating senior management performance[108]. - The company has established a mechanism for profit distribution decisions, requiring board proposals to be submitted for shareholder approval[170]. - The company is committed to improving its governance structure and ensuring that independent directors fulfill their responsibilities to protect the legal rights of minority shareholders[167]. Environmental and Social Responsibility - The company has established a wastewater treatment facility with a capacity of 600m³/d, which operates continuously[136]. - The company utilizes a natural gas boiler for low nitrogen emissions and has installed noise reduction facilities in its boiler room[136]. - The company has constructed a new anaerobic reactor with a capacity of approximately 200 cubic meters for wastewater treatment[137]. - The company has established proper waste storage facilities for medical, hazardous, and general industrial waste in compliance with regulations[136]. - All companies reported no administrative penalties due to environmental issues during the reporting period[155]. Strategic Partnerships and Acquisitions - The company completed the acquisition of 45% equity in GDS, a global leader in blood testing instruments and reagents, enhancing its capabilities in quality control and product safety[38]. - Following the completion of overseas mergers and acquisitions, the company established a strategic partnership with its major shareholder, enhancing its market share and industry position through various collaborative mechanisms[34]. - The company has a robust merger and acquisition strategy, having successfully integrated three domestic blood product companies between 2014 and 2016, significantly increasing raw plasma collection and optimizing product structure[37]. Research and Development - The company increased its R&D investment, focusing on both blood products and other biopharmaceutical fields, and expanded its R&D projects during the reporting period[33]. - The company's R&D investment amounted to ¥129,019,787.36 in 2021, a decrease of 0.52% compared to ¥129,692,987.55 in 2020, with R&D expenditure accounting for 3.01% of operating revenue, down from 4.70%[54]. - The company aims to improve product quality through ongoing research, including studies on the quality of intravenous immunoglobulin and human albumin[53]. Employee and Management Practices - The total number of employees at the end of the reporting period was 2,966, with 3,204 employees receiving salaries during the period[119]. - The company has 1,141 technical personnel, 501 production personnel, and 242 sales personnel, indicating a strong focus on technical expertise[119]. - In 2021, the company implemented various training programs, including leadership training for frontline managers and skills training for all employees[121]. - The company aims to maintain a leading position in employee income within the industry through performance-based salary adjustments and bonuses[120].

Financial Performance - The company's revenue for Q3 2021 reached ¥1,290,798,229.69, representing a 77.12% increase year-over-year[4] - Net profit attributable to shareholders was ¥485,745,026.42, up 21.78% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was ¥493,141,228.70, reflecting a 31.00% increase year-over-year[4] - Total operating revenue for Q3 2021 reached ¥3,046,522,817.78, a significant increase of 49.5% compared to ¥2,038,065,381.23 in the same period last year[34] - Net profit attributable to the parent company was ¥1,396,174,488.18, up 27.5% from ¥1,095,585,062.50 in Q3 2020[35] - The total comprehensive income for the quarter was ¥1,302,063,087.04, compared to ¥1,143,009,910.62 in Q3 2020, reflecting a growth of 13.9%[36] - Basic and diluted earnings per share were both ¥0.207, an increase from ¥0.173 in the same quarter last year[36] Assets and Liabilities - The total assets at the end of the reporting period were ¥27,674,138,664.36, an increase of 8.55% from the end of the previous year[4] - The company's total liabilities amounted to ¥1,408,825,920.90, an increase of 287.5% from ¥363,735,006.80 year-on-year[32] - The company's current assets reached CNY 6,874,982,757.45, up from CNY 5,012,129,176.45, indicating a significant increase of about 37.2% year-over-year[75] - The company's non-current assets totaled CNY 20,799,155,906.91, an increase from CNY 20,481,669,440.48, reflecting a growth of approximately 1.6%[75] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥1,180,273,101.83, showing a significant increase of 65.02% compared to the previous year[7] - The cash inflow from operating activities for the current period is CNY 3,074,672,754.43, compared to CNY 2,186,506,603.25 in the previous period, representing an increase of approximately 40.5%[38] - The net cash flow from operating activities is CNY 1,180,273,101.83, up from CNY 715,225,594.02 in the previous period, indicating a growth of about 65%[38] - The cash outflow from financing activities totals CNY 554,057,332.69, compared to CNY 68,393,592.20 in the previous period, showing a substantial increase of approximately 707%[39] Shareholder Information - Grifols, S.A. is the largest shareholder, holding 26.20% of shares, equivalent to 1,766,165,808 shares[8] - Kory Tiancheng Investment Holding Co., Ltd. holds 13.18% of shares, totaling 888,731,326 shares, with 888,196,426 shares frozen[8] - RAAS China Limited owns 8.13% of shares, amounting to 548,158,853 shares, all of which are frozen[8] - The top ten shareholders collectively hold significant stakes, with the largest three shareholders accounting for over 47.51% of total shares[8] - The company has verified that there are no related party relationships among the top ten shareholders, except for Kory Tiancheng and RAAS China[11] Strategic Agreements and Projects - The company has entered into an exclusive agency agreement with Grifols International, with an estimated total amount of approximately $282.92 million for 2021[13] - The agreement allows Shanghai Laishi and its subsidiaries to act as exclusive distributors for Grifols products in designated areas[13] - The planned total investment for the Southern Headquarters and Inspection Center project is 2 billion RMB, aimed at enhancing production operations and long-term business development[16] - The company has received approval for the production of human albumin and is set to resume sales following the issuance of the relevant production license[18] - The strategic cooperation agreement with Grifols aims to resolve industry competition issues and enhance market share[15] Inventory and Accounts Receivable - The company reported a significant increase in accounts receivable, totaling ¥598,243,053.83, a rise of 48.30% year-over-year, attributed to a substantial increase in sales revenue[6] - The company’s inventory increased by 34.12% due to a rise in imported albumin product stock during the reporting period[6] Legal and Financial Issues - The company has filed a lawsuit seeking repayment of CNY 197,029,490, including principal and late fees, from Shenzhen Xifeng and its controlling parties[28] - The company has fully recognized bad debt losses related to the aforementioned contract dispute, indicating no significant impact on the current year's performance[27] - The court has initiated enforcement proceedings against Shenzhen Xifeng for the outstanding equity transfer payment, with the assessed value of the equity at 50.36 million RMB[69] Research and Development - Research and development expenses for the quarter were ¥77,743,274.40, representing an increase of 12.5% from ¥69,389,351.35 in the previous year[35]

上海莱士血液制品股份有限公司 2021 年半年度报告 披露日期：2021 年 08 月 20 日 上海莱士血液制品股份有限公司 2021 年半年度报告全文 1 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人陈杰先生、主管会计工作负责人陈杰先生及会计机构负责人 (会计主管人员)赵曦女士声明：保证本半年度报告中财务报告的真实、准确、 完整。 所有董事均已出席了审议本报告的董事会会议。 本报告所涉及的公司发展情况是基于当前形势的预计，不构成公司对投资 | --- | |---------------------------------------------------------------------------| | | | | | 者的实质性承诺，公司可能存在原材料供应风险、血浆成本上升风险、产品潜 | | 在的安全性风险、商誉减值风险等，具体内容详见本报告第三节 管理层讨论与 | | 分析 之 " 十、公司面临的风险和应对措施 " ，敬请广大投资者注意投资风险 ...